ER-positive and/or HER2-positive/claudin-low breast cancers represent approximately one-third of all claudin-low cancers and thus, attempts to use triple negativity in immunohistochemistry (potentially together with other markers) as a surrogate for claudin-low status would miss this significant subset [35]. This evidence concerns the gene ESR1 and breast carcinoma.